Sacral nerve stimulation controls bladder functions by implanting a device that delivers controlled electrical impulses to the sacral nerves that modulate the neurological pathways. Patients with fecal and urinary problems can benefit from this safe and effective treatment.
The market for sacral nerve stimulation in 2021 was USD 3.27 billion, and it will be worth USD 10.70 billion by 2030, growing at a 14.07% CAGR during 2021-2030.
Around 13 million persons in the U.S. suffer from urine incontinence, with women making up the majority of those affected, according to the Centres for Medicare and Medicaid Services. Furthermore, women are more prone than men to have urinary incontinence.
The two stages of sacral nerve stimulation are the evaluation and implant phases. The rise in chronic urinary disorders increased investment in research-related activities, and technical advances in the pharmaceutical and medical device sectors will propel the global sacral nerve stimulation market.
The rising prevalence of urinary tract diseases, rising demand for minimally invasive therapy, a sizable population pool in developing nations, and technological advancements like the introduction of novel coatings and engineering techniques are the factors propelling the global sacral nerve stimulation market. Over 55,000 men and 17,000 women are diagnosed with bladder cancer each year in the United States, and 5,000 women and 11,000 men pass away from the disease, according to the Centers for Disease Control and Prevention. The prevalence of urinary system cancer, urinary tract infections, and rising consumer spending have driven the global market for sacral nerve stimulation.
Health risks associated with nerve stimulation and unfavorable regulatory regulations limit the market’s growth. In addition, the high price tags attached to the treatments will also restrain market expansion.
Due to the aging population, screening for lung cancer programs will have additional commercial opportunities. According to a study published in Therapeutic Advances in Urology, urinary tract infections (UTIs) were the most common illnesses seen in outpatient settings (2019). Elderly women were disproportionately affected by UTIs, with 205 (or 11% of the population under investigation) suffering from UTIs. These populations will accelerate the segment’s growth by stimulating demand for the therapy.
On the basis of product, the market for sacral nerve stimulation is segmented into implantable and external.
In 2020, the Implantable Devices segment held a maximum market position with 68.33% of the revenue share. An implantable device with a needle is incorporated to accurately control bladder function, and the procedure can be done without the need for surgery. As a result, treatment with this device is extremely advantageous for individuals suffering from urge incontinence, which is driving the expansion of this category. According to one study, incontinence affects over 300 million people worldwide each year, accounting for nearly 5% of the global population.
On The Basis Of Application
the sacral nerve stimulation market is segmented into chronic anal fissure, urge incontinence, urinary & fecal incontinence, and others.
In 2020, the urinary & fecal incontinence segment ruled the overall market with the largest share due to the ongoing rise in obstetric trauma, interstitial cystitis, voiding dysfunction, and fecal impaction. According to a research study, over 16 out of every 100 persons worldwide have constipation problems. Nearly 33 out of 100 persons in the older population have major constipation problems.
In 2020, North America led the entire regional market with the largest revenue share of 45.13% due to ongoing expansion in the senior population and a growing desire for minimally invasive procedures. According to the Administration for Community Living, the number of Americans 60 and over increased by almost 34% between 2009 and 2019, from 55.7 million to 74.6 million.
On the other hand, Asia Pacific was the rapidly growing regional market due to a sudden rise in the number of patients with fecal and urine incontinence. According to a study, there are between 43 and 349 million persons in China over the age of 60 who experience urine incontinence.
- Axonics Modulation Technologies
- Codman & Shurtleff
- St. Jude Medical
- Synapse Biomedical
- Boston Scientific Corporation
- Nevro Corp.
The market for sacral nerve stimulation in 2021 was USD 3.27 billion, and it will be worth USD 10.70 billion by 2030, growing at a 14.07% CAGR during 2021-2030. Major drivers of the market expansion are the rise in cases of urge incontinence, including urinary tract infections (UTIs), the number of patients with overactive bladders (OABs), and fecal incontinence.